Literature DB >> 17260012

Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.

G Jönsson1, C Dahl, J Staaf, T Sandberg, P-O Bendahl, M Ringnér, P Guldberg, A Borg.   

Abstract

Malignant melanoma is an aggressive, heterogeneous disease where new biomarkers for diagnosis and clinical outcome are needed. We searched for chromosomal aberrations that characterize its pathogenesis using 47 different melanoma cell lines and tiling-resolution bacterial artificial chromosome-arrays for comparative genomic hybridization. Major melanoma genes, including BRAF, NRAS, CDKN2A, TP53, CTNNB1, CDK4 and PTEN, were examined for mutations. Distinct copy number alterations were detected, including loss or gain of whole chromosomes but also minute amplifications and homozygous deletions. Most common overlapping regions with losses were mapped to 9p24.3-q13, 10 and 11q14.1-qter, whereas copy number gains were most frequent on chromosomes 1q, 7, 17q and 20q. Amplifications were delineated to oncogenes such as MITF (3p14), CCND1 (11q13), MDM2 (12q15), CCNE1 (19q12) and NOTCH2 (1p12). Frequent findings of homozygous deletions on 9p21 and 10q23 confirmed the importance of CDKN2A and PTEN. Pair-wise comparisons revealed distinct sets of alterations, for example, mutually exclusive mutations in BRAF and NRAS, mutual mutations in BRAF and PTEN, concomitant chromosome 7 gain and 10 loss and concomitant chromosome 15q22.2-q26.3 gain and 20 gain. Moreover, alterations of the various melanoma genes were associated with distinct chromosomal imbalances suggestive of specific genomic programs in melanoma development.

Entities:  

Mesh:

Year:  2007        PMID: 17260012     DOI: 10.1038/sj.onc.1210252

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

Review 1.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

3.  Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

Authors:  Katherine L Nathanson; Anne-Marie Martin; Bradley Wubbenhorst; Joel Greshock; Richard Letrero; Kurt D'Andrea; Steven O'Day; Jeffrey R Infante; Gerald S Falchook; Hendrik-Tobias Arkenau; Michael Millward; Michael P Brown; Anna Pavlick; Michael A Davies; Bo Ma; Robert Gagnon; Martin Curtis; Peter F Lebowitz; Richard Kefford; Georgina V Long
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

4.  Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.

Authors:  Guo Chen; Nitin Chakravarti; Kimberly Aardalen; Alexander J Lazar; Michael T Tetzlaff; Bradley Wubbenhorst; Sang-Bae Kim; Scott Kopetz; Alicia A Ledoux; Y N Vashisht Gopal; Cristiano Goncalves Pereira; Wanleng Deng; Ju-Seog Lee; Katherine L Nathanson; Kenneth D Aldape; Victor G Prieto; Darrin Stuart; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

5.  Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor.

Authors:  Miguel F Segura; Douglas Hanniford; Silvia Menendez; Linsey Reavie; Xuanyi Zou; Silvia Alvarez-Diaz; Jan Zakrzewski; Elen Blochin; Amy Rose; Dusan Bogunovic; David Polsky; Jianjun Wei; Peng Lee; Ilana Belitskaya-Levy; Nina Bhardwaj; Iman Osman; Eva Hernando
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

6.  Integrative genome comparison of primary and metastatic melanomas.

Authors:  Omar Kabbarah; Cristina Nogueira; Bin Feng; Rosalynn M Nazarian; Marcus Bosenberg; Min Wu; Kenneth L Scott; Lawrence N Kwong; Yonghong Xiao; Carlos Cordon-Cardo; Scott R Granter; Sridhar Ramaswamy; Todd Golub; Lyn M Duncan; Stephan N Wagner; Cameron Brennan; Lynda Chin
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

7.  The retinoblastoma protein modulates Tbx2 functional specificity.

Authors:  Keith W Vance; Heather M Shaw; Mercedes Rodriguez; Sascha Ott; Colin R Goding
Journal:  Mol Biol Cell       Date:  2010-06-09       Impact factor: 4.138

8.  Novel primate-specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool.

Authors:  Josane F Sousa; Raul Torrieri; Rodrigo R Silva; Cristiano G Pereira; Valeria Valente; Erico Torrieri; Kamila C Peronni; Waleska Martins; Nair Muto; Guilherme Francisco; Carla Abdo Brohem; Carlos G Carlotti; Silvya S Maria-Engler; Roger Chammas; Enilza M Espreafico
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

9.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

Review 10.  Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  J Cell Mol Med       Date:  2009-09-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.